Fotoféresis extracorpórea versus tratamiento alternativo para la enfermedad injerto contra huésped crónica posterior al trasplante de células madre hematopoyéticas en pacientes pediátricos
References
References to studies excluded from this review
Abu‐Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A, Djulbegovic B, et al. Extracorporeal photopheresis in steroid‐refractory acute or chronic graft‐versus‐host disease: results of a systematic review of prospective studies. Biology of Blood and Marrow Transplantation 2014;20:1677‐86.
Apisarnthanarax N, Donato M, Korbling M, Couriel D, Gajewski J, Giralt S, et al. Extracorporeal photopheresis therapy in the management of steroid‐refractory or steroid‐dependent cutaneous chronic graft‐versus‐host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplantation 2003;31(6):459‐65.
Balda B, Konstantinov A, Starz H, Gneklow A, Heidemann P. Extracorporeal photochemotherapy as an effective treatment modality in chronic graft versus host disease. Journal of the European Academy of Dermatology and Venereology 1996;7:155‐62.
Besnier DP, Chabannes D, Mahe B, Mussini JM, Baranger TA, Muller JY, et al. Treatment of graft‐versus‐host disease by extracorporeal photochemotherapy: a pilot study. Transplantation 1997;64(1):49‐54.
Biagi E, Perseghin P, Buscemi F, Dassi M, Rovelli A, Balduzzi A. Effectiveness of extracorporeal photochemotherapy in treating refractory chronic graft‐versus‐host disease. Haematologica 2000;85(3):329‐30.
Bisaccia E, Palangio M, Gonzalez J. Long‐term extracorporeal photochemotherapy in a pediatric patient with refractory sclerodermatous chronic graft‐versus‐host disease. Transfusion and Apheresis Science 2011;45(2):187‐90.
Bruserud O, Tvedt THA, Paulsen PQ, Ahmed AB, Gedde‐Dahl T, Tjonnfjord GE, et al. Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: i mmunological mechanisms and the results from clinical studies. Cancer Immunology, Immunotherapy 2014;63:757‐77.
Child FJ, Ratnavel R, Watkins P, Samson D, Apperley J, Ball J, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft‐versus‐host disease (GVHD). Bone Marrow Transplantation 1999;23(9):881‐7.
D'Incan M, Kanold J, Halle P, De Lumley L, Souteyrand P, Demeocq F. Extracorporeal photopheresis as an alternative therapy for drug‐resistant graft versus host disease: three cases. Annales de Dermatologie et de Venereologie 2000;127(2):166‐70.
Dall'Amico R, Rossetti F, Zulian F, Montini G, Murer L, Andreetta B, et al. Photopheresis in paediatric patients with drug‐resistant chronic graft‐versus‐host disease. British Journal of Haematology 1997;97(4):848‐54.
Das‐Gupta E, Greinix H, Jacobs R, Zhou L, Savani BN, Engelhardt BG, et al. Extracorporeal photopheresis as second‐line treatment for acute graft‐versus‐host disease: impact on six‐month freedom from treatment failure. Haematologica 2014;99:1746‐52.
Dhir S, Slatter M, Skinner R. Recent advances in the management of graft‐versus‐host disease. Archives of Disease of Childhood 2014;99:1150‐7.
Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft‐versus‐host disease. Blood 2008;112(7):2667‐74.
Foss FM. Extracorporeal photopheresis in the treatment of graft‐vs‐host disease. Journal of Cutaneous Medicine and Surgery 2003;7(4 Suppl):13‐7.
Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, et al. Prospective study of extracorporeal photopheresis in steroid‐refractory or steroid‐resistant extensive chronic graft‐versus‐host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplantation 2005;35(12):1187‐93.
Halle P, Paillard C, D'Incan M, Bordigoni P, Piguet C, De Lumley L, et al. Successful extracorporeal photochemotherapy for chronic graft‐versus‐host disease in pediatric patients. Journal of Hematotherapy & Stem Cell Research 2002;11(3):501‐12.
Jagasia M, Greinix H, Robin M, Das‐Gupta E, Jacobs R, Savani BN, et al. Extracorporeal photopheresis versus anticytokine therapy as a second‐line treatment for steroid‐refractory acute GVHD: a multicenter comparative analysis. Biology of Blood and Marrow Transplantation 2013;19:1129‐33.
Kanold J, Paillard C, Halle P, D'Incan M, Bordigoni P, Demeocq F. Extracorporeal photochemotherapy for graft versus host disease in pediatric patients. Transfusion and Apheresis Science 2003;28(1):71‐80.
Kanold J, Messina C, Halle P, Locatelli F, Lanino E, Cesaro S, et al. Update on extracorporeal photochemotherapy for graft‐versus‐host disease treatment. Bone Marrow Transplantation 2005;35(Suppl 1):S69‐71.
Kanold J, Merlin E, Halle P, Paillard C, Marabelle A, Rapatel C, et al. Photopheresis in pediatric graft‐versus‐host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007;47(12):2276‐89.
Looks A, Fuchs D, Rulke D, Lange D, Zintl F, Wollina U. Successful treatment of acute graft versus host disease after bone marrow transplantation in 16‐year old girl with extracorporeal photopheresis. Onkologie 1996;7:155‐62.
Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G, Cesaro S, et al. Extracorporeal photochemotherapy for paediatric patients with graft‐versus‐host disease after hematopoietic stem cell transplantation. British Journal of Haematology 2003;122(1):118‐27.
Perotti C, Torretta L, Viarengo G, Roveda L, Bernuzzi S, Carbone S, et al. Feasibility and safety of a new technique of extracorporeal photochemotherapy: experience of 240 procedures. Haematologica 1999;84(3):237‐41.
Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F, et al. Statement of current majority practices in graft‐versus‐host disease prophylaxis and treatment in children. Bone Marrow Transplantation 2000;26(4):405‐11.
Rossetti F, Zulian F, Dall'Amico R, Messina C, Montini G, Zacchello F. Extracorporeal photochemotherapy as single therapy for extensive, cutaneous, chronic graft‐versus‐host disease. Transplantation 1995;59(1):149‐51.
Rossetti F, Dall'Amico R, Crovetti G, Messina C, Montini G, Dini G, et al. Extracorporeal photochemotherapy for the treatment of graft‐versus‐host disease. Bone Marrow Transplantation 1996;18(Suppl 2):175‐81.
Salvaneschi L, Perotti C, Zecca M, Bernuzzi S, Viarengo G, Giorgiani G, et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001;41(10):1299‐305.
Zecca M, Locatelli F. Management of graft‐versus‐host disease in paediatric bone marrow transplant recipients. Paediatric Drugs 2000;2(1):29‐55.
Additional references
Jump to:
Akpek G, Lee SM, Anders V, Vogelsang GB. A high‐dose pulse steroid regimen for controlling active chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2001;7(9):495‐502.
Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S, et al. Performance of a new clinical grading system for chronic graft‐versus‐host disease: a multicenter study. Blood 2003;102(3):802‐9.
Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, et al. Activation‐induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. International Immunology 2007;19(4):345‐54.
Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, et al. Global and organ‐specific chronic graft‐versus‐host disease severity according to the 2005 NIH Consensus Criteria. Blood 2010;118(15):4242‐49.
Atkinson K, Horowitz MM, Gale RP, Van Bekkum DW, Gluckman E, Good RA, et al. Risk factors for chronic graft‐versus‐host disease after HLA‐identical sibling bone marrow transplantation. Blood 1990;75(12):2459‐64.
Barrett AJ, Le Blanc K. Prophylaxis of acute GVHD: manipulate the graft or the environment?. Best Practice and Research. Clinical Haematology 2008;21(2):165‐76.
Beredjiklian PK, Drummond DS, Dormans JP, Davidson RS, Brock GT, August C. Orthopaedic manifestations of chronic graft‐versus‐host disease. Journal of Pediatric Orthopedics 1998;18(5):572‐5.
Bethea D, Fullmer B, Syed S, Seltzer G, Tiano J, Rischko C, et al. Psoralen photobiology and photochemotherapy: 50 years of science and medicine. Journal of Dermatological Science 1999;19(2):78‐88.
Billingham RE. The biology of graft‐versus‐host reactions. Harvey Lectures 1966;62:21‐78.
Bladon J, Taylor PC. The down‐regulation of IL1alpha and IL6, in monocytes exposed to extracorporeal photopheresis (ECP)‐treated lymphocytes, is not dependent on lymphocyte phosphatidylserine externalization. Transplant International 2006;19(4):319‐24.
Bolanos‐Meade J, Vogelsang GB. Chronic graft‐versus‐host disease. Current Pharmaceutical Design 2008;14(20):1974‐86.
Brickl R, Schmid J, Koss FW. Clinical pharmacology of oral psoralen drugs. Photo‐dermatology 1984;1(4):174‐86.
Bunin NJ, Davies SM, Aplenc R, Camitta BM, DeSantes KB, Goyal RK, et al. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. Journal of Clinical Oncology 2008;26(26):4326‐32.
Busca A, Saroglia EM, Lanino E, Manfredini L, Uderzo C, Nicolini B, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplantation 2000;25(10):1067‐71.
Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, et al. Prospective evaluation of 2 acute graft‐versus‐host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM‐TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005;106(4):1495‐500.
Chosidow O, Bagot M, Vernant JP, Roujeau JC, Cordonnier C, Kuentz M, et al. Sclerodermatous chronic graft‐versus‐host disease. Analysis of seven cases. Journal of the American Academy of Dermatology 1992;26(1):49‐55.
Cooke K, Yanik G. Lung injury following hematopoietic cell transplantation. In: Appelbaum F, Forman S, Negrin R editor(s). Thomas' Hematopoietic Cell Transplantation. 4th Edition. Oxford: Wiley‐Blackwell, 2009:1456‐72.
Couriel D, Carpenter PA, Cutler C, Bolanos‐Meade J, Treister NS, Gea‐Banacloche J, et al. Ancillary therapy and supportive care of chronic graft‐versus‐host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biology of Blood and Marrow Transplantation 2006;12(4):375‐96.
Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid‐refractory chronic graft‐versus‐host disease. Blood 2006;108(2):756‐62.
Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft‐versus‐host disease. Therapeutic Apheresis 2002;6(4):296‐304.
De Bueger M, Bakker A, Bontkes H, van Rood JJ, Goulmy E. High frequencies of cytotoxic T cell precursors against minor histocompatibility antigens after HLA‐identical BMT: absence of correlation with GVHD. Bone Marrow Transplantation 1993;11(5):363‐8.
Deeks J, Higgins J, Altman D. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Diaconescu R, Storb R. Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care. Journal of Cancer Research and Clinical Oncology 2005;131(1):1‐13.
Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft‐versus‐host disease: analysis of risk factors and treatment outcomes. Biology of Blood and Marrow Transplantation 2003;9(10):657‐66.
Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR, Ringdén O, et al. the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. Higher mortality after allogeneic peripheral‐blood transplantation compared with bone marrow in children and adolescents. Journal of Clinical Oncology 2004;22(24):4872‐80.
Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, et al. Treatment of cutaneous T‐cell lymphoma by extracorporeal photochemotherapy. Preliminary results. New England Journal of Medicine 1987;316(6):297‐303.
Ferrara JL, Deeg HJ. Graft‐versus‐host disease. New England Journal of Medicine 1991;324(10):667‐74.
Ferrara JLM. Antin J. The pathophysiology of graft‐vs‐host disease. In: Blume KG, Forman SJ, Appelbaum FR editor(s). Thomas' Hematopoietic Cell Transplantation. 3rd Edition. Malden, MA: Blackwell Science, 2004:353‐68.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: I. Diagnosis and Staging Working Group report. Biology of Blood and Marrow Transplantation 2005;11(12):945‐56.
Fimiani M, Di Renzo M, Rubegni P. Mechanism of action of extracorporeal photochemotherapy in chronic graft‐versus‐host disease. British Journal of Dermatology 2004;150(6):1055‐60.
Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI, et al. Comparison of chronic graft‐versus‐host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long‐term follow‐up of a randomized trial. Blood 2002;100(2):415‐9.
Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Petersdorf EW, Pereira SE, et al. Comparative analysis of risk factors for acute and for chronic graft‐versus‐host‐disease according to National Institute of Health consensus criteria. Blood 2011;117(11):3214‐9.
Fraser CJ, Scott Baker K. The management and outcome of chronic graft‐versus‐host disease. British Journal of Haematology 2007;138(2):131‐45.
Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A, et al. Biomarkers in newly diagnosed pediatric‐extensive chronic graft‐versus‐host disease: a report from the Children's Oncology Group. Blood 2008;111(6):3276‐85.
Gaziev J, Lucarelli G. Hematopoietic stem cell transplantation for thalassemia. Current Stem Cell Research and Therapy 2010;6(2):162‐9.
Gilman AL, Chan KW, Mogul A, Morris C, Goldman FD, Boyer M, et al. Hydroxychloroquine for the treatment of chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2000;6(3A):327‐34.
Gilman AL, Serody J. Diagnosis and treatment of chronic graft‐versus‐host disease. Seminars in Hematology 2006;43(1):70‐80.
Girardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Transfusion and Apheresis Science 2002;26(3):181‐90.
Goldberg JD, Jacobsohn DA, Margolis J, Chen AR, Anders V, Phelps M, et al. Pentostatin for the treatment of chronic graft‐versus‐host disease in children. Journal of Pediatric Hematology/Oncology 2003;25(7):584‐8.
Hackstein H, Misterek J, Nockher A, Reiter A, Bein G, Woessmann W. Mini buffy coat photopheresis for children and critically ill patients with extracorporeal photopheresis contraindications. Transfusion 2009;49(11):2366‐73.
Heald P, Perez M, McKiernan G, Christiensen I, Edelson R. Extracorporeal photochemotherapy: indications, methodology, safety aspects, side effects and long‐term results. Photo‐dermatology1989; Vol. 6, issue 4:171‐6.
Heshmati F. Mechanisms of action of extracorporeal photochemotherapy. Transfusion and Apheresis Science 2003;29(1):61‐70.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higman MA, Vogelsang GB. Chronic graft versus host disease. British Journal of Haematology 2004;125(4):435‐54.
Horowitz M. Uses and growth of hematopoietic cell transplantation. In: Forman J AF editor(s). Thomas' Hematopoietic Cell Transplantation. 3rd Edition. Malden, MA: Blackwell Science, 2004:9‐15.
Jacobsohn DA, Gilman AL, Rademaker A, Browning B, Grimley M, Lehmann L, et al. Pediatric Blood and Marrow Transplant Consortium study. Evaluation of pentostatin in corticosteroid‐refractory chronic graft‐versus‐host disease in children. Blood 2009;114(20):4354‐60.
Jacobsohn DA. Optimal management of chronic graft‐versus‐host disease in children. British Journal of Haematology 2010;150(3):278‐92.
Jagasia MH, Savani BN, Stricklin G, Engelhardt B, Kassim A, Dixon S, et al. Classic and overlap chronic graft‐versus‐host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biology of Blood and Marrow Transplantation2009; Vol. 15, issue 10:1288‐95.
Janin A, Socie G, Devergie A, Aractingi S, Esperou H, Verola O, et al. Fasciitis in chronic graft‐versus‐host disease. A clinicopathologic study of 14 cases. Annals of Internal Medicine1994; Vol. 120, issue 12:993‐8.
Johnston LJ, Brown J, Shizuru JA, Stockerl‐Goldstein KE, Stuart MJ, Blume KG, et al. Rapamycin (sirolimus) for treatment of chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2005;11(1):47‐55.
Kennedy‐Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, et al. Comparable outcomes of matched‐related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biology of Blood and Marrow Transplantation 2006;12(12):1277‐84.
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9.
Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Therapy for chronic graft‐versus‐host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100(1):48‐51.
Lamioni A, Parisi F, Isacchi G, Giorda E, Di Cesare S, Landolfo A, et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005;79(7):846‐50.
Lee SJ, Vogelsang G, Flowers ME. Chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2003; Vol. 9, issue 4:215‐33.
Legitimo A, Consolini R, Failli A, Fabiano S, Bencivelli W, Scatena F, et al. In vitro treatment of monocytes with 8‐methoxypsolaren and ultraviolet A light induces dendritic cells with a tolerogenic phenotype. Clinical and Experimental Immunology 2007;148(3):564‐72.
Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ, et al. Relation of an interleukin‐10 promoter polymorphism to graft‐versus‐host disease and survival after hematopoietic‐cell transplantation. New England Journal of Medicine 2003;349(23):2201‐10.
Lopez F, Parker P, Nademanee A, Rodriguez R, Al‐Kadhimi Z, Bhatia R, et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2005;11(4):307‐13.
Maeda A, Schwarz A, Kernebeck K, Gross N, Aragane Y, Peritt D, et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen‐specific regulatory T cells. Journal of Immunology 2005;174(10):5968‐76.
Martin PJ. Biology of chronic graft‐versus‐host disease: implications for a future therapeutic approach. The Keio Journal of Medicine 2008;57(4):177‐83.
Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft‐versus‐host disease. Blood 2009;113(21):5074‐82.
Meisel R, Laws HJ, Balzer S, Bernbeck B, Kramm C, Schonberger S, et al. Comparable long‐term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies. Biology of Blood and Marrow Transplantation 2007;13(11):1338‐45.
Melin‐Aldana H, Thormann K, Duerst R, Kletzel M, Jacobsohn DA. Hepatitic pattern of graft versus host disease in children. Pediatric Blood and Cancer2007; Vol. 49, issue 5:727‐30.
Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H‐Y minor histocompatibility antigens correlate with chronic graft‐versus‐host disease and disease remission. Blood 2005;105(7):2973‐8.
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13.
Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft‐versus‐host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplantation 1999;24(5):517‐20.
Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I‐minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen‐specific cytotoxic T lymphocytes in patients with graft‐versus‐host disease. Nature Medicine 1999;5(7):839‐42.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.
Pavletic SZ, Carter SL, Kernan NA, Henslee‐Downey J, Mendizabal AM, Papadopoulos E, et al. Influence of T‐cell depletion on chronic graft‐versus‐host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005;106(9):3308‐13.
Perotti C, Del Fante C, Tinelli C, Viarengo G, Scudeller L, Zecca M, et al. Extracorporeal photochemotherapy in graft‐versus‐host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion 2010;50(6):1359‐69.
Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplantation 2003;31(4):229‐39.
Przepiorka D, Weisdorf D, Martin P, Klingemann H G, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825‐8.
Ram R, Gafter‐Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O. Prophylaxis regimens for GVHD: systematic review and meta‐analysis. Bone Marrow Transplantation 2009;43(8):643‐53.
Rappeport JM, O'Reilly RJ, Kapoor N, Parkman R. Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us. Hematology/Oncology Clinics of North America 2011;25(1):17‐30.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rocha V, Wagner JE, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, et al. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. Graft‐versus‐host disease in children who have received a cord‐blood or bone marrow transplant from an HLA‐identical sibling. New England Journal of Medicine 2000;342(25):1846‐54.
Salmasian H, Rohanizadegan M, Banihosseini S, Rahimi Darabad R, Rabbani‐Anari M, Shakiba A, et al. Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD005565.pub2]
Scarisbrick JJ, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T‐cell lymphoma and chronic graft‐versus‐host disease. British Journal of Dermatology 2008;158(4):659‐78.
Schooneman F. Extracorporeal photopheresis technical aspects. Transfusion and Apheresis Science 2003;28(1):51‐61.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12.
Shah AJ, Kapoor N, Crooks GM, Weinberg KI, Azim HA, Killen R, et al. The effects of Campath 1H upon graft‐versus‐host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biology of Blood and Marrow Transplantation 2007;13(5):584‐93.
Shimada K, Yokozawa T, Atsuta Y, Kohno A, Maruyama F, Yano K, et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplantation 2005;36(2):115‐21.
Shulman HM, Sullivan KM. Graft‐versus‐host disease: allo‐ and autoimmunity after bone marrow transplantation. Concepts in Immunopathology 1988;6:141‐65.
Smith EP, Sniecinski I, Dagis AC, Parker PM, Snyder DS, Stein AS, et al. Extracorporeal photochemotherapy for treatment of drug‐resistant graft‐vs.‐host disease. Biology of Blood and Marrow Transplantation 1998;4(1):27‐37.
Sniecinski I. Extracorporeal photochemotherapy: a scientific overview. Transfusion Science 1994;15(4):429‐37.
Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft‐versus‐host disease. Blood 2004;104(12):3501‐6.
Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft‐versus‐host disease. Blood 1986;68(1):119‐25.
Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, et al. Chronic graft‐versus‐host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981;57(2):267‐76.
Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, et al. Alternating‐day cyclosporine and prednisone for treatment of high‐risk chronic graft‐v‐host disease. Blood 1988;72(2):555‐61.
Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft‐v‐host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988;72(2):546‐54.
Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft‐versus‐host disease and other late complications of bone marrow transplantation. Seminars in Hematology 1991;28(3):250‐9.
Sullivan K. Graft‐versus‐host disease. In: Blume KG, Forman SJ, Appelbaum FR editor(s). Thomas Hematopoietic Cell Transplantation. 3rd Edition. Malden, MA: Blackwell Science, 2004:633‐64.
Szodoray P, Papp G, Nakken B, Harangi M, Zeher M. The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation. Autoimmunity Reviews 2010;9(6):459‐64.
Toubai T, Sun Y, Reddy P. GVHD pathophysiology: is acute different from chronic?. Best Practice and Research. Clinical Haematology 2008;21(2):101‐17.
Treister NS, Woo SB, O'Holleran EW, Lehmann LE, Parsons SK, Guinan EC. Oral chronic graft‐versus‐host disease in pediatric patients after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 2005;11(9):721‐31.
Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, et al. Thalidomide for the treatment of chronic graft‐versus‐host disease. New England Journal of Medicine 1992;326(16):1055‐8.
Vogelsang GB. How I treat chronic graft‐versus‐host disease. Blood 2001;97(5):1196‐201.
Voss CY, Fry TJ, Coppes MJ, Blajchman MA. Extending the horizon for cell‐based immunotherapy by understanding the mechanisms of action of photopheresis. Transfusion Medicine Reviews 2010;24(1):22‐32.
Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000;95(6):1918‐24.
Walters MC. Stem cell therapy for sickle cell disease: transplantation and gene therapy. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2005;2005:66‐73.
Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine 2002;21(22):3337‐51.
Wingard JR, Vogelsang GB, Deeg HJ. Stem cell transplantation: supportive care and long‐term complications. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;2002:422‐44.
Wolff D, Schleuning M, Von Harsdorf S, Bacher U, Gerbitz A, Stadler M, et al. Consensus conference on clinical practice in chronic GVHD: second‐line treatment of chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2011;17(1):1‐17.
Xia CQ, Campbell KA, Clare‐Salzler MJ. Extracorporeal photopheresis‐induced immune tolerance: a focus on modulation of antigen‐presenting cells and induction of regulatory T cells by apoptotic cells. Current Opinion in Organ Transplantation 2009;14(4):338‐43.
Yoo EK, Rook AH, Elenitsas R, Gasparro FP, Vowels BR. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T‐cell lymphoma: relevance to mechanism of therapeutic action. Journal of Investigative Dermatology 1996;107(2):235‐42.
Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C, et al. Chronic graft‐versus‐host disease in children: incidence, risk factors, and impact on outcome. Blood 2002;100(4):1192‐200.
Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S, et al. Donor CD4+ T and B cells in transplants induce chronic graft‐versus‐host disease with autoimmune manifestations. Blood 2006;107(7):2993‐3001.
References to other published versions of this review
Jump to:
Weitz M, Strahm B, Meerpohl JJ, Bassler D. Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in paediatric patients. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD009898]
Weitz M, Strahm B, Meerpohl JJ, Bassler D. Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in paediatric patients. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD009898.pub2]
Characteristics of studies
Characteristics of excluded studies [ordered by study ID]
| Study | Reason for exclusion |
| Review article reporting on efficacy of ECP for aGvHD and cGvHD treatment | |
| Retrospective study on 2 paediatric patients and 62 adults with cGvHD | |
| Case report of 1 child with cGvHD | |
| Case series of 3 paediatric patients and 4 adults with aGvHD (2 children) and cGvHD (5 children) | |
| Case report of paediatric patients with cGvHD | |
| Case report of paediatric patient with cGvHD | |
| Review article reporting on results from clinical studies of ECP treatment in aGvHD and cGvHD | |
| Case series of 11 adults with cGvHD | |
| Case series of 3 paediatric patients with GvHD | |
| Case series of 4 paediatric patients with cGvHD | |
| Retrospective, uncontrolled study on 128 patients (less than 50% paediatric) with aGvHD | |
| Review article reporting on pathobiology of cGvHD/aGvHD, biomarker development and treatment strategies | |
| Multicentre prospective phase 2 randomised controlled study in people with cGvHD including less than 50% children | |
| Review reporting case series | |
| Study not randomised, not controlled. Prospective, single‐arm study of 23 adults and 2 children with chronic cutaneous or visceral GvHD | |
| Case series of 8 paediatric patients with cGvHD | |
| Retrospective study on 98 patients (less than 50% paediatric) with aGvHD | |
| Case series of paediatric patients with cGvHD | |
| Review article reporting case series of paediatric patients with aGvHD or cGvHD treated with ECP | |
| Prospective, not randomised, study in paediatric patients with aGvHD or cGvHD treated with ECP | |
| Case report of paediatric patient with aGvHD | |
| Prospective, not randomised, uncontrolled study of 77 paediatric patients with acute (33 children) or chronic (44 children) immunosuppressive‐resistant GvHD | |
| Prospective, not randomised, uncontrolled study in paediatric patients with aGvHD (1 child) and cGvHD (6 children) | |
| Review article reporting different therapeutic options for GvHD | |
| Case report of 1 child with cGvHD | |
| Case series of 9 paediatric patients with aGvHD (1 child) and cGvHD (8 children) | |
| Case series of 9 children with aGvHD and 13 children with cGvHD | |
| Review article reporting different therapeutic options for GvHD |
aGvHD: acute graft‐versus‐host disease; cGvHD: chronic graft‐versus‐host disease; ECP: extracorporeal photopheresis; GvHD: graft‐versus‐host disease.
Figures and Tables -
Figure 1
Identification of potentially eligible studies.
Figures and Tables -
Figure 2
Identification of potentially eligible studies for 2015 update.
